Lux Biosciences, Inc.

INVESTORS

SV Life Sciences
www.svlsa.com

SV Life Sciences is a venture capital adviser and manager that makes selected investments in businesses with experienced entrepreneurs and management teams.

SV Life Sciences provides finance to businesses at all stages of development and across the human life sciences sector. These sectors range from biotechnology & pharmaceuticals to medical devices & instruments, to healthcare information technology and services. SV Life Sciences currently advises or manages five funds with capital commitments of approximately $1.5 billion, which primarily invest amounts of between $1m and $40m in North America and Europe, but will consider innovative investments in other regions. The SV Life Sciences team of 32 professionals has a diverse, complementary set of skills and experience that allows it to tailor a team to work with almost any life sciences business.

HBM Partners
www.hbmpartners.com

HBM Partners AG, founded in 2001, is one of the world’s leading investment advisory groups in the sectors of biotechnology, emerging pharma and medical technology. The group invests globally in private, as well as public companies. The HBM team of professionals has extensive experience in drug and medical device development and international operations. Currently, HBM Partners AG manages and advises several investment entities with assets of over US$1 billion. Out of HBM’s private equity portfolio 23 companies have gone public and 8 companies were sold to strategic buyers.

Novo A/S
www.novo.dk

Novo A/S is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation.

The Novo Ventures team consists of six Partners in Copenhagen, one in London and two in San Francisco. With an evergreen structure, Novo A/S annually invests approximately $75 million in venture capital into private life sciences companies, and thus acts at a pace comparable to a traditional $350-400 million fund.

In total Novo A/S has more than $8 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S.

Prospect Venture Partners
www.propectventures.com

Prospect Venture Partners is a Palo Alto, California based venture capital firm with over $1B of capital under management. The firm is dedicated to investing in outstanding biomedical technology and life science companies. Prospect targets commercially attractive medical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovative technology or services with potential for significant investment returns. The partners at Prospect have lead investments in over 75 companies during the past 10 years and have a successful track record of working closely with entrepreneurial management teams in early stage enterprises. Prospect partners and advisors have held senior industry executive positions at a broad range of companies across the biotechnology, medical device and pharmaceutical industries.

International Biotechnology Trust PLC
www.internationalbiotrust.com

International Biotechnology Trust plc is a publicly quoted investment trust listed on the London Stock Exchange (ticker IBT), with total net asset value of approximately $121m as of 30 April, 2006. IBT has an investment focus on later stage private and smaller cap listed life sciences stocks and typical investment size is $1 to $5m.

SVLS became advisers to the trust in November 2000 and Manager on 1 January 2005.